JP2020534540A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020534540A5 JP2020534540A5 JP2020516740A JP2020516740A JP2020534540A5 JP 2020534540 A5 JP2020534540 A5 JP 2020534540A5 JP 2020516740 A JP2020516740 A JP 2020516740A JP 2020516740 A JP2020516740 A JP 2020516740A JP 2020534540 A5 JP2020534540 A5 JP 2020534540A5
- Authority
- JP
- Japan
- Prior art keywords
- napi2b
- cancer
- seq
- antibody
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 46
- 206010028980 Neoplasm Diseases 0.000 claims description 34
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 30
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 30
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 21
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 21
- 239000000611 antibody drug conjugate Substances 0.000 claims description 17
- 229940049595 antibody-drug conjugate Drugs 0.000 claims description 17
- 206010033128 Ovarian cancer Diseases 0.000 claims description 13
- 201000011510 cancer Diseases 0.000 claims description 13
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 10
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 10
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 10
- 206010038389 Renal cancer Diseases 0.000 claims description 10
- 201000010982 kidney cancer Diseases 0.000 claims description 10
- 208000009956 adenocarcinoma Diseases 0.000 claims description 8
- 230000004043 responsiveness Effects 0.000 claims description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 6
- 201000005202 lung cancer Diseases 0.000 claims description 6
- 208000020816 lung neoplasm Diseases 0.000 claims description 6
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 6
- 230000008685 targeting Effects 0.000 claims description 5
- 206010004593 Bile duct cancer Diseases 0.000 claims description 4
- 206010014733 Endometrial cancer Diseases 0.000 claims description 4
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 4
- 206010033701 Papillary thyroid cancer Diseases 0.000 claims description 4
- 208000026900 bile duct neoplasm Diseases 0.000 claims description 4
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 4
- 238000001514 detection method Methods 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 239000013612 plasmid Substances 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims description 4
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 claims description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
- 238000010191 image analysis Methods 0.000 claims description 3
- 229910052697 platinum Inorganic materials 0.000 claims description 3
- 201000002510 thyroid cancer Diseases 0.000 claims description 3
- 101710114425 Homeobox protein Nkx-2.1 Proteins 0.000 claims description 2
- 102100027893 Homeobox protein Nkx-2.1 Human genes 0.000 claims description 2
- 101710088547 Thyroid transcription factor 1 Proteins 0.000 claims description 2
- 101710159262 Transcription termination factor 1 Proteins 0.000 claims description 2
- 230000000762 glandular Effects 0.000 claims description 2
- 238000000386 microscopy Methods 0.000 claims description 2
- -1 napsin A Proteins 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 210000001685 thyroid gland Anatomy 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 1
- 238000000399 optical microscopy Methods 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000000562 conjugate Substances 0.000 description 1
- 210000001581 salivary duct Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762561107P | 2017-09-20 | 2017-09-20 | |
| US62/561,107 | 2017-09-20 | ||
| US201762571397P | 2017-10-12 | 2017-10-12 | |
| US62/571,397 | 2017-10-12 | ||
| US201862718692P | 2018-08-14 | 2018-08-14 | |
| US62/718,692 | 2018-08-14 | ||
| PCT/US2018/051951 WO2019060542A2 (en) | 2017-09-20 | 2018-09-20 | COMPOSITIONS AND METHODS FOR PREDICTING RESPONSE TO NAPI2B TARGETING THERAPY |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020534540A JP2020534540A (ja) | 2020-11-26 |
| JP2020534540A5 true JP2020534540A5 (enExample) | 2021-10-28 |
| JP7279026B2 JP7279026B2 (ja) | 2023-05-22 |
Family
ID=63963394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020516740A Active JP7279026B2 (ja) | 2017-09-20 | 2018-09-20 | Ｎａｐｉ２ｂ標的化療法に対する応答を予測するための組成物および方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11596694B2 (enExample) |
| EP (1) | EP3685166A2 (enExample) |
| JP (1) | JP7279026B2 (enExample) |
| KR (1) | KR20200055770A (enExample) |
| CN (1) | CN111492246A (enExample) |
| AU (1) | AU2018337947A1 (enExample) |
| BR (1) | BR112020005390A2 (enExample) |
| CA (1) | CA3075798A1 (enExample) |
| IL (1) | IL273252B2 (enExample) |
| MX (1) | MX2020003214A (enExample) |
| TW (1) | TW201929906A (enExample) |
| WO (1) | WO2019060542A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3109790A1 (en) | 2018-08-17 | 2020-02-20 | Mersana Therapeutics, Inc. | Napi2b-targeted polymer antibody-drug conjugates and methods of use thereof |
| KR20220056176A (ko) | 2019-08-02 | 2022-05-04 | 메르사나 테라퓨틱스, 인코포레이티드 | 암 치료를 위한 sting(인터페론 유전자의 자극인자) 작용제로서의 비스-[n-((5-카바모일)-1h-벤조[d]이미다졸-2-일)-피라졸-5-카복사미드] 유도체 및 관련 화합물 |
| TW202140075A (zh) | 2020-01-09 | 2021-11-01 | 美商梅爾莎納醫療公司 | 具有含肽之連接子的位置特異性抗體－藥物共軛體 |
| MY210304A (en) | 2020-04-02 | 2025-09-10 | Mersana Therapeutics Inc | Antibody drug conjugates comprising sting agonists |
| AU2021321586A1 (en) | 2020-08-07 | 2023-03-16 | Dana-Farber Cancer Institute, Inc. | Therapeutic targeting of phosphate dysregulation in cancer via the XPR1:KIDINS220 protein complex |
| WO2022168774A1 (ja) * | 2021-02-08 | 2022-08-11 | 株式会社島津製作所 | 推定装置、学習装置、最適化装置、推定方法、学習方法、および最適化方法 |
| CA3266931A1 (en) * | 2022-10-19 | 2024-04-25 | Zymeworks Bc Inc | ANTI-NAPI2B ANTIBODIES AND METHODS OF USE |
| CN119948062A (zh) * | 2022-10-19 | 2025-05-06 | 酵活英属哥伦比亚有限公司 | 靶向napi2b的抗体-药物缀合物及其使用方法 |
| TW202530268A (zh) * | 2023-10-19 | 2025-08-01 | 加拿大商酵活英屬哥倫比亞有限公司 | 抗ｎａｐｉ２ｂ抗體－藥物結合物及使用方法 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE3900534A1 (de) * | 1989-01-10 | 1990-07-12 | Boehringer Mannheim Gmbh | Diagnostischer nachweis unter verwendung von chimaeren antikoerpern |
| CH694588A5 (de) | 1999-02-09 | 2005-04-15 | Hoffmann La Roche | Menschliche intestinale Npt2B. |
| WO2004006955A1 (en) | 2001-07-12 | 2004-01-22 | Jefferson Foote | Super humanized antibodies |
| US20030162254A1 (en) | 2002-01-15 | 2003-08-28 | Peerce Brian E. | NaPi type IIb polypeptides and methods for making and using same |
| NZ583292A (en) | 2003-11-06 | 2012-03-30 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugation to ligands |
| EP1740954B1 (en) * | 2004-04-07 | 2015-08-19 | Genentech, Inc. | Mass spectrometry of antibody conjugates |
| MXPA06014065A (es) * | 2004-06-01 | 2007-01-31 | Genentech Inc | Conjugados de droga-anticuerpo y metodos. |
| US8383799B2 (en) | 2006-01-20 | 2013-02-26 | Cell Signaling Technology, Inc. | Translocation and mutant ROS kinase in human non-small cell lung carcinoma |
| JP5535638B2 (ja) | 2006-10-25 | 2014-07-02 | ウィスコンシン アルムニ リサーチ ファンデイション | リン酸塩吸収の低減方法 |
| BRPI0907648B1 (pt) | 2008-01-29 | 2022-01-11 | Institute Of Molecular Biology And Genetics National Academy Of Science Of Ukraine | Anticorpo isolado humanizado, usos de um anticorpo, métodos para preparar um anticorpo, para gerar anticorpos imunorreativos com slc34a2 e para triar ou identificar agentes ou compostos que modulam slc34a2, composições, ácido nucleico isolado, e, microorganismo hospedeiro |
| WO2009099741A1 (en) * | 2008-02-01 | 2009-08-13 | Genentech, Inc. | Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods |
| MX2011000509A (es) | 2008-07-15 | 2011-04-05 | Genentech Inc | Conjugados derivados de antraciclina, proceso para su preparacion y su uso como compuestos antitumorales. |
| JP5370826B2 (ja) | 2009-04-20 | 2013-12-18 | 株式会社パソロジー研究所 | 癌の組織型を判別するカクテル抗体、判別キット及び判別方法 |
| AU2010324686B2 (en) | 2009-11-30 | 2016-05-19 | Genentech, Inc. | Antibodies for treating and diagnosing tumors expressing SLC34A2 (TAT211 = SEQID2 ) |
| JP5827328B2 (ja) | 2010-07-07 | 2015-12-02 | アーデリクス，インコーポレーテッド | リン酸輸送を阻害する化合物及び方法 |
| WO2012006474A2 (en) | 2010-07-07 | 2012-01-12 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
| EP2590656B1 (en) | 2010-07-07 | 2017-11-15 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
| EP2590655B1 (en) | 2010-07-07 | 2015-06-24 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
| WO2012080822A2 (en) * | 2010-12-14 | 2012-06-21 | Recepta Biopharma S.A. | Antitumor peptide derived from a complementarity determining region of a humanized monoclonal antibody to napi2b transporter |
| KR101972303B1 (ko) * | 2011-06-10 | 2019-04-25 | 메르사나 테라퓨틱스, 인코포레이티드 | 단백질-중합체-약물 접합체 |
| ES2726850T3 (es) | 2013-10-11 | 2019-10-09 | Mersana Therapeutics Inc | Conjugados de proteína-polímero-fármaco |
| PL3054992T3 (pl) | 2013-10-11 | 2020-01-31 | Asana Biosciences, Llc | Koniugaty białko-polimer-lek |
| BR112016024672A2 (pt) * | 2014-04-25 | 2021-02-02 | Exelixis, Inc | método para o tratamento de adenocarcinoma de pulmão |
| TWI695011B (zh) * | 2014-06-18 | 2020-06-01 | 美商梅爾莎納醫療公司 | 抗ｈｅｒ２表位之單株抗體及其使用之方法 |
| CN107743586B (zh) | 2015-06-03 | 2021-07-02 | 百时美施贵宝公司 | 用于癌症诊断的抗gitr抗体 |
| EP3322735A4 (en) * | 2015-07-15 | 2019-03-13 | Zymeworks Inc. | ACTIVE CONJUGATED BIS-SPECIFIC ANTIGEN-BONDING CONSTRUCTS |
| CN108369234B (zh) * | 2015-10-23 | 2020-12-01 | 豪夫迈·罗氏有限公司 | 基于标志物分子将个体鉴定为待通过化疗治疗的方法和相关用途 |
| US20170261766A1 (en) | 2016-03-14 | 2017-09-14 | Vance M. Thompson | Contact lens with flexible center and rigid periphery |
| US10287259B2 (en) | 2016-03-14 | 2019-05-14 | The Penn State Research Foundation | Selenazolidine and thiazolidine compounds for treating cancer and other diseases |
| CA3016474A1 (en) | 2016-03-15 | 2017-09-21 | Mersana Therapeutics, Inc. | Napi2b-targeted antibody-drug conjugates and methods of use thereof |
| WO2018237262A1 (en) | 2017-06-22 | 2018-12-27 | Mersana Therapeutics, Inc. | Methods of producing drug-carrying polymer scaffolds and protein-polymer-drug conjugates |
-
2018
- 2018-09-20 CN CN201880074734.0A patent/CN111492246A/zh active Pending
- 2018-09-20 KR KR1020207011297A patent/KR20200055770A/ko not_active Abandoned
- 2018-09-20 AU AU2018337947A patent/AU2018337947A1/en not_active Abandoned
- 2018-09-20 IL IL273252A patent/IL273252B2/en unknown
- 2018-09-20 JP JP2020516740A patent/JP7279026B2/ja active Active
- 2018-09-20 WO PCT/US2018/051951 patent/WO2019060542A2/en not_active Ceased
- 2018-09-20 US US16/136,706 patent/US11596694B2/en active Active
- 2018-09-20 CA CA3075798A patent/CA3075798A1/en active Pending
- 2018-09-20 BR BR112020005390-2A patent/BR112020005390A2/pt not_active IP Right Cessation
- 2018-09-20 TW TW107133186A patent/TW201929906A/zh unknown
- 2018-09-20 EP EP18792596.1A patent/EP3685166A2/en not_active Withdrawn
- 2018-09-20 MX MX2020003214A patent/MX2020003214A/es unknown
-
2023
- 2023-01-26 US US18/160,012 patent/US20230355787A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020534540A5 (enExample) | ||
| Oude Munnink et al. | Therapeutic drug monitoring of monoclonal antibodies in inflammatory and malignant disease: Translating TNF‐α experience to oncology | |
| IL273252B1 (en) | Compositions and methods for predicting response to napi2b-targeted therapy | |
| CN105392800A (zh) | 抗cxcl1、cxcl7和cxcl8抗体及其应用 | |
| ES2753360T3 (es) | Anticuerpos contra PD-L1 y usos de los mismos | |
| Van Cutsem et al. | Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial | |
| Pollock et al. | Increased expression of HER2, HER3, and HER2: HER3 heterodimers in HPV-positive HNSCC using a novel proximity-based assay: implications for targeted therapies | |
| JP2015529199A5 (enExample) | ||
| CN104755501A (zh) | 与赖氨酰氧化酶样蛋白2(loxl2)相关的治疗和诊断方法 | |
| JP7478708B2 (ja) | 胃癌の検出および治療のための組成物および方法 | |
| US11009511B2 (en) | Methods for detecting and/or measuring anti-drug antibodies, in particular treatment-emergent anti-drug antibodies | |
| JP2014517259A (ja) | 胃癌患者の生存期間を予測及び改善する方法 | |
| JP2020510409A5 (enExample) | ||
| JP6940505B2 (ja) | 組成物および癌の発生リスクの評価方法 | |
| JP2014523920A5 (enExample) | ||
| RU2017136863A (ru) | Способы лечения рака легкого | |
| JP2018516244A5 (enExample) | ||
| JP2020515876A (ja) | 肺癌検出のための組成物と方法 | |
| RU2014138586A (ru) | Прогностический биомаркер для лечения рака антителами с повышенной антителозависимой клеточной цитотоксичностью | |
| Buchholz et al. | Prostaglandin E2 receptor EP1 expression in vulvar cancer | |
| JP2018516877A5 (enExample) | ||
| KR20180013878A (ko) | 렌바티닙 및 에베로리무스를 포함하는 병용 요법을 위한 생체표지 | |
| US12433951B2 (en) | Methods of treatment of non-small-cell lung carcinoma using telisotuzumab vedotin | |
| JP5548872B2 (ja) | 大腸がん肝転移マーカー、及び試料中の大腸がん肝転移マーカーの分析方法 | |
| JP7593669B2 (ja) | コンパニオン診断用バイオマーカー組成物およびこれを含むコンパニオン診断用キット |